



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/875,849	09/08/1997	MICHAEL J. BRISKIN	1855.1004-002 (MPI1995-01)	4411
23630	7590	02/02/2010	EXAMINER	
MCDERMOTT WILL & EMERY LLP			SCHWADRON, RONALD B	
28 STATE STREET			ART UNIT	PAPER NUMBER
BOSTON, MA 02109-1775			1644	
NOTIFICATION DATE		DELIVERY MODE		
02/02/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

BostonIPDocket@mwc.com



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
08875849 01	9/8/1997	BRISKIN ET AL.	1855.1004-002 (MPI1995- 1644)

MCDERMOTT WILL & EMERY LLP
28 STATE STREET
BOSTON, MA 02109-1775

EXAMINER

Ron Schwadron, Ph.D.

ART UNIT	PAPER
----------	-------

1644 201001

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The amino acid sequence of SEQ. ID. No. 6 differs from the depiction of said sequence in Figure 3B in that the fifth amino acid from the C-terminus in the Figure is "C" whilst the sequence listing lists said sequence as "Gln". A new Sequence listing addressing said error is required.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D.
Primary Examiner, Art Unit 1644

/Ron Schwadron/
Primary Examiner, Art Unit 1644